63,500 Shares in AtriCure Inc. (ATRC) Acquired by Lockheed Martin Investment Management Co.

Lockheed Martin Investment Management Co. bought a new position in shares of AtriCure Inc. (NASDAQ:ATRC) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 63,500 shares of the medical device company’s stock, valued at approximately $1,216,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Parametric Portfolio Associates LLC boosted its stake in shares of AtriCure by 11.2% in the first quarter. Parametric Portfolio Associates LLC now owns 34,622 shares of the medical device company’s stock worth $663,000 after buying an additional 3,488 shares during the period. Swiss National Bank boosted its stake in shares of AtriCure by 7.0% in the first quarter. Swiss National Bank now owns 54,700 shares of the medical device company’s stock worth $1,048,000 after buying an additional 3,600 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of AtriCure by 24.2% in the first quarter. Bank of New York Mellon Corp now owns 179,586 shares of the medical device company’s stock worth $3,439,000 after buying an additional 35,013 shares during the period. Wells Fargo & Company MN boosted its stake in shares of AtriCure by 131.9% in the first quarter. Wells Fargo & Company MN now owns 112,006 shares of the medical device company’s stock worth $2,145,000 after buying an additional 63,711 shares during the period. Finally, Rockefeller Financial Services Inc. boosted its stake in shares of AtriCure by 185.0% in the first quarter. Rockefeller Financial Services Inc. now owns 11,766 shares of the medical device company’s stock worth $225,000 after buying an additional 7,637 shares during the period. Institutional investors and hedge funds own 79.30% of the company’s stock.

Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

Shares of AtriCure Inc. (NASDAQ:ATRC) traded up 1.51% during mid-day trading on Friday, reaching $21.50. The company’s stock had a trading volume of 224,838 shares. The firm’s market cap is $729.84 million. AtriCure Inc. has a 52-week low of $13.45 and a 52-week high of $23.95. The firm has a 50 day moving average price of $20.47 and a 200 day moving average price of $18.64.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings results on Thursday, May 4th. The medical device company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. AtriCure had a negative return on equity of 19.84% and a negative net margin of 23.78%. The company had revenue of $41.30 million during the quarter, compared to analysts’ expectations of $40.25 million. During the same quarter in the previous year, the firm earned ($0.31) EPS. AtriCure’s revenue was up 15.0% on a year-over-year basis. On average, equities analysts predict that AtriCure Inc. will post ($0.95) EPS for the current fiscal year.

WARNING: This piece was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://transcriptdaily.com/2017/05/20/63500-shares-in-atricure-inc-atrc-acquired-by-lockheed-martin-investment-management-co.html.

A number of brokerages have weighed in on ATRC. Needham & Company LLC reiterated a “buy” rating and issued a $25.00 price target (up from $23.00) on shares of AtriCure in a research report on Friday, May 5th. Zacks Investment Research cut AtriCure from a “buy” rating to a “hold” rating in a research report on Wednesday, May 10th. TheStreet upgraded AtriCure from a “d+” rating to a “c-” rating in a research report on Monday. BTIG Research cut AtriCure from a “buy” rating to a “neutral” rating in a research report on Monday, March 6th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $20.00 price target on shares of AtriCure in a research report on Monday, February 6th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. AtriCure presently has an average rating of “Buy” and a consensus price target of $22.13.

In other news, SVP Andrew L. Lux sold 20,000 shares of the business’s stock in a transaction on Friday, March 17th. The stock was sold at an average price of $18.85, for a total transaction of $377,000.00. Following the completion of the transaction, the senior vice president now owns 85,589 shares of the company’s stock, valued at approximately $1,613,352.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Elizabeth D. Krell sold 10,000 shares of the business’s stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $21.44, for a total value of $214,400.00. Following the transaction, the director now directly owns 24,162 shares of the company’s stock, valued at approximately $518,033.28. The disclosure for this sale can be found here. 10.00% of the stock is currently owned by insiders.

AtriCure Company Profile

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

12 Month Chart for NASDAQ:ATRC

Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply